{
    "data": [
        {
            "id": "4477104",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-29T09:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/108194384/image_108194384.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2021 Prediction Roundup",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4477104-2021-prediction-roundup"
            }
        },
        {
            "id": "4476993",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-27T18:38:44-05:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295493003/image_1295493003.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers: Disciplined Investors Shall Be Rewarded",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106429",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "354282",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4476993-bristol-myers-disciplined-investors-to-be-rewarded"
            }
        },
        {
            "id": "4475244",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-15T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/828348136/image_828348136.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "It's A Good Time To Buy Bristol Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "353039",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4475244-a-good-time-ever-to-buy-bmy"
            }
        },
        {
            "id": "4473564",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-06T06:12:26-05:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297582177/image_1297582177.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Underperformance Is Temporary",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351915",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4473564-bristol-myers-squibb-bmy-stock-underperformance-temporary"
            }
        },
        {
            "id": "4473335",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-03T17:01:52-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310024666/image_1310024666.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Take On Turning Point Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351656",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4473335-take-on-turning-point-therapeutics"
            }
        },
        {
            "id": "4472267",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-29T07:33:26-05:00",
                "isLockedPro": false,
                "commentCount": 130,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301584009/image_1301584009.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers: Value Time Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "350938",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472267-bristol-myers-value-time-again"
            }
        },
        {
            "id": "4471439",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-23T10:03:13-05:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Great Value And Great Pipeline, But Exaggerated Fears",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106413",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "349697",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4471439-bristol-myers-squibb-great-value-and-great-pipeline-but-exaggerated-fears"
            }
        },
        {
            "id": "4470872",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-19T14:19:12-05:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/53388079/image_53388079.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: 5 Reasons To Buy The Current Dip, And 1 Caveat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "349917",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4470872-bristol-myers-squibb-5-reasons-to-buy-the-current-dip-and-1-caveat"
            }
        },
        {
            "id": "4463253",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-28T22:05:58-04:00",
                "isLockedPro": false,
                "commentCount": 125,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: What More Could You Ask For?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "347031",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4463253-bristol-myers-squibb-earnings-stellar-q3-strong-development-pipeline"
            }
        },
        {
            "id": "4461309",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-21T22:40:46-04:00",
                "isLockedPro": false,
                "commentCount": 161,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227594879/image_1227594879.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons To Invest Like Buffett And Buy Bristol Myers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345854",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4461309-3-reasons-to-invest-like-buffett-and-buy-bristol-myers"
            }
        },
        {
            "id": "4460649",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-19T15:43:09-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292355769/image_1292355769.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Oversold Big Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106331",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345596",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460649-bristol-myers-squibb-oversold-big-pharma"
            }
        },
        {
            "id": "4460595",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-19T12:36:30-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Short-Term Market Timing Based On Yield Spread",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345594",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460595-bristol-myers-squibb-short-term-market-timing-yield-spread"
            }
        },
        {
            "id": "4460584",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-19T11:46:38-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Now Is The Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345656",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460584-bristol-myers-squibb-now-is-the-time"
            }
        },
        {
            "id": "4460487",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-18T23:16:57-04:00",
                "isLockedPro": false,
                "commentCount": 72,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300036753/image_1300036753.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Bristol Myers Stock Offers More Than Just A 3.44% Dividend Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345604",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460487-bristol-myers-stock-offers-more-than-just-a-3-44-percent-dividend-yield"
            }
        },
        {
            "id": "4457622",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-29T06:32:19-04:00",
                "isLockedPro": false,
                "commentCount": 175,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310618429/image_1310618429.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Now Too Cheap To Ignore And Set To Soar",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343254",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4457622-bristol-myers-squibb-too-cheap-to-ignore-set-to-soar"
            }
        },
        {
            "id": "4455953",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-18T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 116,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1254899249/image_1254899249.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar And Bristol Myers Squibb Expecting Bempeg Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "61973",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "341882",
                            "type": "sentiment"
                        },
                        {
                            "id": "341518",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4455953-nektar-and-bristol-myers-squibb-expecting-bempeg-approval"
            }
        },
        {
            "id": "4455707",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-16T23:46:43-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Ongoing Disconnect Between Analysts And Traders On Bristol Myers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "341769",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4455707-bristol-myers-stock-ongoing-disconnect-between-analysts-and-traders"
            }
        },
        {
            "id": "4453054",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-01T14:38:54-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1268430935/image_1268430935.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Fairly Valued, But Lagging Its Peers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "339841",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453054-bristol-myers-squibb-fairly-valued-but-lagging"
            }
        },
        {
            "id": "4452736",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-31T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1268181219/image_1268181219.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Why Wall Street Is Wrong About The Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "339675",
                            "type": "sentiment"
                        },
                        {
                            "id": "339721",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4452736-bristol-myers-squibb-why-wall-street-is-wrong-about-the-stock"
            }
        },
        {
            "id": "4450624",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-19T09:53:33-04:00",
                "isLockedPro": false,
                "commentCount": 102,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Not As Much Upside As You Think",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106149",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338026",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4450624-bristol-myers-squibb-not-as-much-upside-as-you-think"
            }
        },
        {
            "id": "4442417",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-29T06:34:34-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253227748/image_1253227748.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Q2 2021 Shows Strength And Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "335138",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4442417-bristol-myers-squibb-q2-2021-shows-strength-and-value"
            }
        },
        {
            "id": "4441250",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-25T09:56:36-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Company: A Good Combination Of Value And Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "334465",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4441250-bristol-myers-squibb-stock-bmy-good-combination-of-value-and-growth"
            }
        },
        {
            "id": "4440971",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-24T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: An Undervalued Dividend Stock With Growth Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "334302",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4440971-bristol-myers-squibb-an-undervalued-dividend-stock-with-growth-potential"
            }
        },
        {
            "id": "4438524",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-09T16:38:25-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277229026/image_1277229026.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is A High Yielding Blue-Chip That Should Appreciate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "332482",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4438524-bristol-myers-squibb-a-high-yielding-blue-chip"
            }
        },
        {
            "id": "4435829",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-21T08:59:48-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/image_1251485261.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Sleuthing: Bristol Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40591",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "330206",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4435829-dividend-sleuthing-bristol-myers-squibb"
            }
        },
        {
            "id": "4434084",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-11T09:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298788278/image_1298788278.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Undervalued, With 13% Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23275",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "328821",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4434084-bristol-myer-undervalued-with-13-percent-upside"
            }
        },
        {
            "id": "4434260",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-11T00:58:13-04:00",
                "isLockedPro": false,
                "commentCount": 98,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/image_1251485261.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb - Don't Miss Out On This",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "328867",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4434260-bristol-myers-squibb-dont-miss-out-on-this"
            }
        },
        {
            "id": "4434090",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-10T08:58:45-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1290196720/image_1290196720.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Strengthening Its Grip On The Oncology And Cardiovascular Disease Drugs Segment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "328842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4434090-bristol-myers-squibb-strengthening-grip-oncology-cardiovascular-disease-drugs"
            }
        },
        {
            "id": "4433827",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-10T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/image_1224202684.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Buy, Hold, Or Sell This Dividend Growth Healthcare Stock?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105975",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "328660",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4433827-bristol-meyers-squibb-buy-hold-or-sell-this-dividend-growth-healthcare-stock"
            }
        },
        {
            "id": "4432143",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-30T16:11:59-04:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1132313828/image_1132313828.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Investment Case Getting Better And Better - A Great Time To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "327431",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4432143-bristol-myers-squibb-investment-case-getting-better-and-better-a-great-time-to-buy"
            }
        },
        {
            "id": "4430593",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-22T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Nvidia, Ford, AT&T And Crypto Names In The Spotlight",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4430593-stocks-to-watch-nvidia-ford-and-crypto-names-in-the-spotlight"
            }
        },
        {
            "id": "4426396",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-09T08:44:51-04:00",
                "isLockedPro": false,
                "commentCount": 222,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/image_1224202684.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Or Bristol-Myers Squibb: Which Is A Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324569",
                            "type": "sentiment"
                        },
                        {
                            "id": "324570",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4426396-pfizer-or-bristol-myers-squibb-which-is-a-better-buy"
            }
        },
        {
            "id": "4422783",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-30T04:25:45-04:00",
                "isLockedPro": false,
                "commentCount": 181,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157559643/image_157559643.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: A Compelling Investment Thesis In A Nutshell",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "323418",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4422783-bristol-myers-earnings-compelling-investment-thesis-in-nutshell"
            }
        },
        {
            "id": "4421318",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-26T13:28:45-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1222751304/image_1222751304.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Our Top Healthcare Pick For The Rest Of 2021",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105308",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "322833",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4421318-bristol-myers-squibb-top-healthcare-pick"
            }
        },
        {
            "id": "4417714",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-05T18:08:05-04:00",
                "isLockedPro": false,
                "commentCount": 178,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184769358/image_184769358.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons Warren Buffett Loves Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "319565",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4417714-3-reasons-warren-buffett-loves-bristol-myers-and-should-you"
            }
        },
        {
            "id": "4416507",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-28T17:18:55-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1278075515/image_1278075515.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb's Floundering Days Could Be Behind It - Full Steam Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "319001",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4416507-bristol-myers-squibbs-floundering-days-behind-full-steam-ahead"
            }
        },
        {
            "id": "4412309",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-08T15:40:24-05:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Contingent Value Rights: Thinking Through The Options Around Litigation Financing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "316344",
                            "type": "sentiment"
                        },
                        {
                            "id": "316345",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4412309-bmyrt-thinking-through-options-around-litigation-financing"
            }
        },
        {
            "id": "4410911",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-03T09:30:07-05:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Warren Buffett Buys Bristol-Myers Squibb, And So Should You",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "315636",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4410911-warren-buffett-buys-bristol-myers-squibb-and-so-should-you"
            }
        },
        {
            "id": "4410179",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-28T16:44:36-05:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Undervalued Dividend Contender, Offering Income, Dividend Growth, And Capital Appreciation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105646",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "315101",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4410179-bristol-myers-squibb-undervalued-dividend-contender-offering-income-dividend-growth-and"
            }
        },
        {
            "id": "4406471",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-16T17:41:18-05:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Has Unique Cash Flow Strength",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "313571",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4406471-bristol-myers-squibb-unique-cash-flow-strength"
            }
        },
        {
            "id": "4406106",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-15T00:51:50-05:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Analysts Think The Market Is All Wrong On Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "313364",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4406106-analysts-think-market-is-all-wrong-on-bristol-myers-squibb"
            }
        },
        {
            "id": "4402514",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-01T14:50:02-05:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Out Of The Rut",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "311500",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4402514-bristol-myers-squibb-out-of-rut"
            }
        },
        {
            "id": "4399087",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-15T10:01:01-05:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Provides Long-Term Guidance: Stock Could Be Poised To Breakout",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24784",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "309003",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4399087-bristol-myers-provides-long-term-guidance-stock-be-poised-to-breakout"
            }
        }
    ]
}